mTOR signaling: implications for cancer and anticancer therapy

[1]  N. Sonenberg,et al.  mTOR signaling: implications for cancer and anticancer therapy. , 2007, British journal of cancer.

[2]  H. Pelicano,et al.  Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells , 2005, Leukemia.

[3]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[4]  D. Kwiatkowski,et al.  Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. , 2005, Human molecular genetics.

[5]  Y. Wang,et al.  Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development , 2005, Leukemia.

[6]  W. Filipowicz,et al.  Inhibition of Translational Initiation by Let-7 MicroRNA in Human Cells , 2005, Science.

[7]  David M Sabatini,et al.  An expanding role for mTOR in cancer. , 2005, Trends in molecular medicine.

[8]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[9]  Paul Tempst,et al.  Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.

[10]  H. Lane,et al.  The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation , 2005, Cell.

[11]  K. Inoki,et al.  Signaling by Target of Rapamycin Proteins in Cell Growth Control , 2005, Microbiology and Molecular Biology Reviews.

[12]  R. Lotan,et al.  Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin , 2005, Cancer biology & therapy.

[13]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[14]  H. Lane,et al.  The mTOR Inhibitor RAD 001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p 21 Translation , 2005 .

[15]  G. Mills,et al.  Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells , 2004, Clinical Cancer Research.

[16]  Johan Auwerx,et al.  Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity , 2004, Nature.

[17]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[18]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[19]  R. DePinho,et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. , 2004, Cancer cell.

[20]  N. Sonenberg,et al.  Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. , 2004, Cancer cell.

[21]  P. Pandolfi,et al.  The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis , 2004, Nature Medicine.

[22]  A. Gingras,et al.  Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases , 2004, The EMBO journal.

[23]  N. Sonenberg,et al.  eIF4E – from translation to transformation , 2004, Oncogene.

[24]  J. Graff,et al.  eIF-4E expression and its role in malignancies and metastases , 2004, Oncogene.

[25]  Stefano Fumagalli,et al.  S6K1−/−/S6K2−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway , 2004, Molecular and Cellular Biology.

[26]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[27]  D. Neuberg,et al.  Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Verstovsek,et al.  Mammalian target of rapamycin inhibition as therapy for hematologic malignancies , 2004, Cancer.

[29]  C. Proud.  mTOR-mediated regulation of translation factors by amino acids. , 2004, Biochemical and biophysical research communications.

[30]  Kun-Liang Guan,et al.  Dysregulation of the TSC-mTOR pathway in human disease , 2004, Nature Genetics.

[31]  D. Sabatini,et al.  Raptor and mTOR: subunits of a nutrient-sensitive complex. , 2004, Current topics in microbiology and immunology.

[32]  A. Lorberg,et al.  TOR: the first 10 years. , 2004, Current topics in microbiology and immunology.

[33]  Ronald A. DePinho,et al.  Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation , 2002, Nature.

[34]  P. Houghton,et al.  4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to Rapamycin* , 2002, The Journal of Biological Chemistry.

[35]  Shile Huang,et al.  Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. , 2002, Current opinion in investigational drugs.

[36]  S. Gygi,et al.  Serum‐stimulated, rapamycin‐sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI , 2000, The EMBO journal.

[37]  A. Gingras,et al.  eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. , 1999, Annual review of biochemistry.

[38]  J. Heitman,et al.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast , 1991, Science.

[39]  N. Sonenberg,et al.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap , 1990, Nature.